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(http://creativecommoAlzheimer’s disease (AD), require the application of a wide range of diagnostic assays. There
is a large unmet need for relatively simple, blood-based biomarkers in this regard. We have
recently developed a rapid and reliable flow cytometry and antibody-based method for the quan-
titative measurement of various red blood cell (RBC) membrane proteins from a drop of blood.
Here, we document that the RBC expression of certain membrane proteins, especially that of the
GLUT1 transporter and the insulin receptor (INSR), is significantly higher in AD patients than in
age-matched healthy subjects. The observed differences may reflect long-term metabolic alter-
ations relevant in the development of AD. These findings may pave the way for a diagnostic
application of RBC membrane proteins as relatively stable and easily accessible personalized
biomarkers in AD.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Red cell membrane proteins; Biomarkers; Insulin receptor; GLUT1 transporter; ABCA1; ABCB6; ABCG2;PMCA; Erythrocyte membrane1. Introduction
Alzheimer’s disease (AD) is manifested in a progressive
dementia that currently affects over 40 million people
worldwide. There are no reliable cures or disease-
modifying therapies available, and there is no early diag-
nostic method to indicate AD before it has progressed to
major memory loss and functional decline [1,2]. Current
biomarkers for this disease, including cerebrospinal fluid
tau and amyloid-b determinations, MRI, and other
imaging methods, are invasive, time-consuming, or
expensive. New biomarkers for predicting the appearance,
determining the progress, and reporting the effects ofntributed equally.
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ns.org/licenses/by/4.0/).disease-modifying or preventative treatments are definitely
required. Blood-based biomarkers may be an attractive
option, but those available from among plasma proteins
or lipids still need higher sensitivity and specificity.
Measuring membrane proteins in blood cell samples may
open a new avenue in this regard [3].
According to our recent work, the quantitative determina-
tion of human red blood cell (RBC) membrane proteins as
biomarkers may offer new diagnostic possibilities. The
expression and function of RBC membrane proteins for
long has been suggested to provide information regarding
various disease conditions and were considered as potential
biomarkers [4]. As examples, in complex metabolic condi-
tions, the RBC adrenergic receptor activation and a related
adenosine triphosphate release, the Na-Li countertransport,
or the alterations of glucose transport and the insulin recep-
tor have been suggested to correlate with disease susceptibil-
ity, treatment response, or complications [5,6].eimer’s Association. This is an open access article under the CC BY license
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cytometry-based diagnostic assay for the quantitative
determination of the ABCG2 membrane protein in the hu-
man erythrocyte membrane [7]. In that work, we have
documented a direct correlation between ABCG2 geno-
types and RBC membrane expression levels, which may
be useful to characterize patients potentially developing
hyperuricemia and becoming afflicted with gout [7]. In
a further study, we found low level RBC expression of
the ABCB6 protein and documented a hereditary genetic
basis for these altered expression levels [8]. Recently,
we have further developed the panel of quantitative mem-
brane protein detection in the RBC membrane, by exam-
ining several transporters and receptors through antibody
binding in flow cytometry [9,10]. These membrane
proteins include the multidrug transporters ABCC1 and
ABCC4, the glucose exchanger GLUT3, the sodium-
glucose transporter SLC5A2 (SGLT2), the uric acid trans-
porters SLC2A9 and URAT1 (SLC22A12), and PLSCR1
(a phospholipase scramblase). In as yet unpublished set
of experiments, we performed quantitative measurements
for these membrane proteins in numerous healthy subjects
and in various multifactorial disease conditions with a
strong metabolic background. An emerging picture based
on these studies suggests a significant regulation of mem-
brane protein expression under altered metabolic condi-
tions, including type 2 diabetes and hyperuricemia/gout
(unpublished data). To compile the potential RBC mem-
brane biomarkers, we also performed mass spectrometry
studies and generated a comprehensive, searchable data-
base for the RBC membrane proteins [11].
In the present study, we have quantitatively analyzed the
changes in the expression levels of several RBC membrane
proteins in the groups of late and early onset AD patients,
already characterized by a wide range of clinical and labora-
tory examinations. In this study, we have selected RBC
membrane proteins based on a bioinformatics and network
analysis of genome-wide association (GWA) studies, Online
Mendelian Inheritance in Man (OMIM), and red blood cell
(RBC) databases [11,12] for a potential involvement in
Alzheimer’s disease. Here, we document that a limited
number of transporters and receptors, potentially relevant
in AD, show significant differences in RBC membrane
expression in the AD patients as compared with normal,
age-matched controls.2. Methods
2.1. Selection of patients and controls
Forty patients diagnosed with Alzheimer’s disease were
included in this study. Twenty-seven of these patients were
considered to have late onset AD (ages.70) and 13 patients
were classified into early onset AD (age ,61). All patients
have been characterized by detailed clinical examinations,
including imaging studies. For patient recruitment, clinicalevaluation, and ethical permission, see the Supplementary
Materials.
General laboratory diagnostic data were obtained at the
University of Szeged, Hungary. For all AD patients and
healthy individuals, the laboratory diagnostics were
performed. The list of laboratory data obtained in this study
and some of the key results are summarized in
Supplementary Table 1.
RBC membrane protein determinations were performed
by flow cytometry, according to our recently developed
method [7–10]. After antibody titration and using
saturating amounts of selected antibodies, we quantitated
the following red cell membrane protein levels: GLUT1
(SLC2A1), ABCA1, ABCB6, ABCG2, INSR, and
PMCA4b. For the details of the RBC labeling, antibody
sources, expression analysis, and statistics, see the
Supplementary Materials.3. Results
In all AD patients and control participants, detailed labo-
ratory blood analytic examinations were performed. As
documented in the Supplementary Table 1, the results of
the laboratory tests showed no specific alterations between
the patients and the control subjects. The only significant dif-
ferences we found were somewhat increased granulocyte
and decreased lymphocyte percentages and elevated alkaline
phosphatase levels in the AD patients, probably reflecting
the mild inflammatory-like conditions characteristic for
this disease [1,4]. Although some studies found altered
levels in the major plasma lipids and lipid-binding proteins
in AD patients [1], we did not observe such differences here.
In addition to the general clinical and laboratory exami-
nations, we have examined the expression levels of several
transporters and the insulin receptor in the RBC membranes
of normal healthy and AD patients. The obtained data indi-
cate that in late onset AD patients (Fig. 1A), the RBC mem-
brane expression levels of the GLUT1 transporter and the
insulin receptor (INSR) were significantly increased. In
addition, we found significantly increased RBC membrane
expression levels for the ABCA1 and the ABCG2 trans-
porters, as compared with those in the age-matched control
subjects. No measurable changes were observed in the
expression levels of the plasma membrane calcium pump
(PMCA) and the ABCB6 transporter.
In early onset AD patients (Fig. 1B), the results also
showed a significant increase for the RBC membrane
expression of GLUT1 and INSR, whereas we did not find
significant alterations in the RBC membrane expression
levels for ABCA1, ABCG2, PMCA, and ABCB6 between
the early onset AD patients and the age-matched controls.
When examining potential gender-related differences in
these RBC membrane protein expression levels, we did not
observe any significant differences either in the group of
late or early onset AD patients and normal subjects
(not shown).
Fig. 1. Expression of RBC membrane proteins in AD patients and age-matched control individuals, measured by flow cytometry. For details, see text and
Supplementary Materials. Panel (A): Values obtained in late onset AD patients (ages.70 years) and age-matched controls. Panel (B): Values obtained in early
onset AD patients (ages,61 years) and age-matched controls. (A) Late onset AD. (B) Early onset AD. Abbreviations: RBC, red blood cell; AD, Alzheimer’s
disease; PMCA, plasma membrane calcium pump.
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The mentioned data indicate major changes in the
expression levels of metabolically relevant membrane
transporters and a receptor in the RBCmembrane of AD pa-
tients. The GLUT1 (SLC2A1) transporter is an abundant
membrane protein in the human RBC, with an expression
of about 100,000 copies per cell. The other main physiolog-
ical sites of human GLUT1 expression are the blood-brain
barrier endothelial cells, cardiac muscle, adipocytes, kid-
ney cortex mesangial cells, and brain astrocytes. GLUT1
expression is tissue-dependently regulated by circulating
glucose levels, hypoxia, as well as hormones, including
insulin and growth hormones [13,14], and it has been
shown that chronic hyperglycemia increases RBC
GLUT1 expression [15]. According to our present results,
GLUT1 expression was significantly greater in both late
and early onset AD patients than in age-matched controls,
whereas systemic hyperglycemia was not apparent in the
patients. Based on the relevant literature [1,2,16], we
hypothesize that this increase in RBC reflects an
upregulation of this transporter in the blood-brain barrier
endothelial cells, caused by the relative metabolic starva-
tion and/or hypoxia in the brain tissues.The insulin receptor (INSR) in the human RBC was
shown to have the same basic features as in other tissues
[17], a reduced binding of insulin to RBC-INSR was
observed in non–insulin-dependent diabetes, and in hy-
pertension with hyperinsulinemia [18]. In the present
study, we observed a significant increase in RBC-INSR
in both late and early onset AD patients. This may reflect
an overall upregulation of the INSR expression, caused
by the relative insulin deficiency in the central nervous
system (CNS) [1,2].
The ABCA1 protein is involved in the formation of high-
density lipoprotein (HDL) cholesterol and the reverse choles-
terol transport from the liver and various cell types [19] and is
present in the human RBC [9–11]. Here, we found that in late
onset AD, this protein is significantly increased in the RBC
membrane, which may reflect a long-term regulatory
response in cholesterol transport, not apparent in the actual
plasma cholesterol or binding protein levels.
The ABCG2 multidrug transporter has a role in xenobi-
otic transport and cancer drug resistance, uric acid transport,
and was identified as the junior blood group component [20].
We have shown a cosegregation of low RBC-ABCG2
expression with mutant variants [7], whereas here, we found
Fig. 1. (continued).
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greater than in the age-matched controls. An earlier study
from our group found lower prevalence of the Q141K-
ABCG variant in AD patients [21], whereas a higher protein
expression in RBC, shown here, may reflect a general upre-
gulation of ABCG2, indicated to play a role in protecting the
CNS against amyloid accumulation [22]. In this study, we
found that the RBC membrane expression of PMCA4 (the
“housekeeping” calcium pump) and ABCB6 (the Lan blood
group component) was unchanged in AD.
The observed increase in the GLUT1, INSR, ABCA1,
and ABCG2 expression in the RBC membrane of late
onset AD patients may indicate underlying metabolic
alterations and probably a general upregulation of these
proteins also in tissues related to the CNS, reflecting sys-
temic transcriptional or translational effects. The increase
in GLUT1 and INSR in early onset AD suggests similar
metabolic alterations in this disease. Obviously, further
and larger cohort studies are required to establish a rela-
tionship of the expression of these RBC membrane
proteins with treatment protocols, therapeutic responses,
or complications in AD. Because the membrane proteins
studied here have also been implicated in major meta-
bolic diseases, including type 2 diabetes and gout, over-
lapping disease mechanisms may be also reflected by
the RBC membrane biomarkers. In our preliminary, as
yet unpublished studies, we found that in insulin-resistant type 2 diabetes patients, the expression of
GLUT1 in RBC is significantly upregulated, whereas
the level of INSR, in contrast to that in the AD patients,
is greatly reduced. Of course, further detailed studies are
required to appreciate these changes, and the determina-
tion of additional RBC membrane proteins may provide
a panel for differential diagnostics of various metabolic
alterations.
Interestingly, the red cell membrane contains more than
300 different membrane proteins, ([11] http://rbcc.hegelab.
org/) among which several may be diagnostically relevant
in AD. These include the amyloid-b-A4protein, a-synu-
clein, presenilin-1, nicastrin, acetylcholinesterase, ABCA7,
phospholipid-scramblases, or the GLUT3 transporter. We
are currently installing quantitative assays for these further
RBC membrane proteins, whereas the limited availability
of specific, high affinity antibodies and the costs for purchas-
ing and selecting such antibodies are hindering these efforts.
Still, based on the easy accessibility of red cells, this
methodology may provide new possibilities for membrane
protein biomarker diagnostics in AD and related multifacto-
rial diseases.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.dadm.2015.06.007.
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1. Systematic review: To follow progression and poten-
tial therapeutic effects, the laboratory diagnostics of
Alzheimer’s disease (AD) requires multiple, prefer-
ably noninvasive, and inexpensive new tools.
Blood-based biomarkers may serve this need.
2. Interpretation: Our current data indicate that a quan-
titative determination of the expression level of
certain red blood cell (RBC) membrane proteins by
flow cytometry may offer new potential biomarkers
in AD. We document that the expression of the
GLUT1 sugar transporter and the insulin receptor
in the RBC membrane of the AD patients is signifi-
cantly increased. Similar tendency is observed for
the ABCA1 lipid transporter and the ABCG2 multi-
drug transporter.
3. Future directions: A detailed analysis of the expres-
sion of these and several more RBC membrane pro-
teins may help to construct a relatively simple and
inexpensive diagnostic panel for supporting AD di-
agnostics. This technology may also help to under-
stand the pathologic regulatory effects underlying
this disease.
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